PT3126521T - Gene de fusão hnf4g-rspo2 - Google Patents

Gene de fusão hnf4g-rspo2

Info

Publication number
PT3126521T
PT3126521T PT15772589T PT15772589T PT3126521T PT 3126521 T PT3126521 T PT 3126521T PT 15772589 T PT15772589 T PT 15772589T PT 15772589 T PT15772589 T PT 15772589T PT 3126521 T PT3126521 T PT 3126521T
Authority
PT
Portugal
Prior art keywords
hnf4g
fusion gene
rspo2 fusion
rspo2
gene
Prior art date
Application number
PT15772589T
Other languages
English (en)
Inventor
Cai Jie
Li Henry
Original Assignee
Crown Bioscience Inc Taicang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crown Bioscience Inc Taicang filed Critical Crown Bioscience Inc Taicang
Publication of PT3126521T publication Critical patent/PT3126521T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT15772589T 2014-04-04 2015-04-03 Gene de fusão hnf4g-rspo2 PT3126521T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410135569 2014-04-04

Publications (1)

Publication Number Publication Date
PT3126521T true PT3126521T (pt) 2019-06-27

Family

ID=54239415

Family Applications (2)

Application Number Title Priority Date Filing Date
PT15772589T PT3126521T (pt) 2014-04-04 2015-04-03 Gene de fusão hnf4g-rspo2
PT157738402T PT3126528T (pt) 2014-04-04 2015-04-03 Métodos para determinar a responsividade a inibidores de mek/erk

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT157738402T PT3126528T (pt) 2014-04-04 2015-04-03 Métodos para determinar a responsividade a inibidores de mek/erk

Country Status (7)

Country Link
US (3) US10501805B2 (pt)
EP (3) EP3126528B1 (pt)
CN (3) CN111808957A (pt)
DK (2) DK3126521T3 (pt)
ES (2) ES2896404T3 (pt)
PT (2) PT3126521T (pt)
WO (2) WO2015149721A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102413458B1 (ko) * 2016-08-04 2022-06-24 시즈오카켄 암의 발증 리스크의 유무를 판정하는 방법
US11612643B2 (en) 2016-09-30 2023-03-28 Genoimmune Therapeutics Co, , Ltd. Col14A1-derived tumor antigen polypeptide and use thereof
JP2022517563A (ja) * 2019-01-02 2022-03-09 チョーチアン クラウンマブ バイオテック カンパニー リミテッド タンパク質キナーゼバイオマーカーと組み合わせた、多標的キナーゼ阻害剤を使用したがんの処置
CN111434353A (zh) * 2019-02-02 2020-07-21 中国科学院上海营养与健康研究所 Ras抑制剂筛选及疗效标志物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4503035B1 (en) 1978-11-24 1996-03-19 Hoffmann La Roche Protein purification process and product
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US5231176A (en) 1984-08-27 1993-07-27 Genentech, Inc. Distinct family DNA encoding of human leukocyte interferons
DE69032864T3 (de) 1989-03-29 2013-01-31 The Johns Hopkins University Nachweis des Ausfalls des Wildtyps des p53-Gens
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
DE69629826T2 (de) 1995-10-23 2004-07-01 Children's Medical Center Corp., Boston Therapeutische antiangiogenische zusammensetzungen und verfahren
WO1997019110A1 (en) 1995-11-23 1997-05-29 Cancer Research Campaign Technology Limited Materials and methods relating to the identification and sequencing of the brca2 cancer susceptibility gene and uses thereof
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
TR199900048T2 (xx) 1996-07-13 1999-04-21 Glaxo Group Limited Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler
ES2239393T3 (es) 1997-05-07 2005-09-16 Sugen, Inc. Derivados de 2-indolinona utilizados como moduladores de la actividad de la proteina-quinasa.
EP0984692A4 (en) 1997-05-30 2001-02-21 Merck & Co Inc ANGIOGENESIS INHIBITORS
WO1999010349A1 (en) 1997-08-22 1999-03-04 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
JP2001518470A (ja) 1997-09-26 2001-10-16 メルク エンド カムパニー インコーポレーテッド 新規な血管形成阻害剤
BR9814018A (pt) 1997-11-11 2000-09-26 Pfizer Prod Inc Derivados de tienopirimidina e tienopiridina úteis como agentes anticâncer
WO1999061422A1 (en) 1998-05-29 1999-12-02 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
PT2050749T (pt) 2006-08-08 2018-01-02 Chugai Pharmaceutical Co Ltd Derivado de pirimidina como inibidador de pi3k e sua utilização
SG174826A1 (en) 2006-09-19 2011-10-28 Novartis Ag Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
CL2009000241A1 (es) 2008-02-07 2010-09-03 Chugai Pharmaceutical Co Ltd Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer.
CN101524529B (zh) * 2008-03-04 2011-09-28 中国人民解放军第二军医大学 HNF4α诱导分化治疗人体恶性实体瘤
WO2010096660A2 (en) * 2009-02-19 2010-08-26 Cornell University Compositions and methods for diagnosing prostate cancer based on detection of slc45a3-elk4 fusion transcript
CA2759233C (en) 2009-04-27 2019-07-16 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
US8945556B2 (en) * 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
MX2013005668A (es) 2010-11-19 2013-11-04 Glaxosmithkline Ip No 2 Ltd Metodo de tratamiento con inhibidor de braf.
WO2012106559A1 (en) * 2011-02-02 2012-08-09 Translational Genomics Research Institute Biomarkers and methods of use thereof
CN103571848B (zh) 2012-08-10 2016-06-29 安徽医科大学第一附属医院 点状掌跖角化病的致病基因及其用途

Also Published As

Publication number Publication date
EP3126528A1 (en) 2017-02-08
US10683550B2 (en) 2020-06-16
PT3126528T (pt) 2021-09-09
US20170114414A1 (en) 2017-04-27
US20180282814A1 (en) 2018-10-04
US20200123622A1 (en) 2020-04-23
EP3126528A4 (en) 2018-02-21
CN106460060B (zh) 2020-02-11
CN111808957A (zh) 2020-10-23
ES2727374T3 (es) 2019-10-15
EP3126528B1 (en) 2021-08-18
US10501805B2 (en) 2019-12-10
EP3126521A4 (en) 2017-11-08
EP4012049A3 (en) 2022-08-24
DK3126528T3 (da) 2021-11-08
WO2015149720A1 (en) 2015-10-08
DK3126521T3 (da) 2019-06-17
ES2896404T3 (es) 2022-02-24
EP4012049A2 (en) 2022-06-15
EP3126521B1 (en) 2019-03-20
CN106536753A (zh) 2017-03-22
CN106460060A (zh) 2017-02-22
CN106536753B (zh) 2020-07-21
WO2015149721A1 (en) 2015-10-08
EP3126521A1 (en) 2017-02-08

Similar Documents

Publication Publication Date Title
GB201413019D0 (en) Beyond 1B
AU361515S (en) Dishrack
GB201517022D0 (en) No details
HK1232136A1 (zh) 融合蛋白
GB201410907D0 (en) No details
GB201519531D0 (en) No details
AU362944S (en) Lapboard
GB201517404D0 (en) No details
GB201418217D0 (en) No details
GB201418216D0 (en) No details
GB201517412D0 (en) No details
IL249254B (en) Gene expression system
GB201516796D0 (en) No details
GB201517574D0 (en) No details
IL257500A (en) Altered cullin1 gene
PT3126521T (pt) Gene de fusão hnf4g-rspo2
GB2539126B (en) Interface
SG11201702844VA (en) Photobioreactor
SG11201606501PA (en) Nanobody-fluorescent protein fusion
GB201517605D0 (en) No details
GB201410910D0 (en) No details
GB201402083D0 (en) Retaining means
GB201801971D0 (en) No details
GB201608944D0 (en) Gene Tharapy
GB201604701D0 (en) No Details